Literature DB >> 62911

How strong is the case for intensive cancer chemotherapy?

M H Tattersall, J S Tobias.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 62911     DOI： 10.1016/s0140-6736(76)90979-x

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

Review 1.  High dose chemotherapy with autologous marrow rescue in the treatment of resistant solid tumors.

Authors:  C F LeMaistre; W A Knight
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

Review 2.  Intensive chemotherapy for solid tumours--current clinical applications.

Authors:  S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

3.  The average relative dose intensity of R-CHOP is an independent factor determining favorable overall survival in diffuse large B-cell lymphoma patients.

Authors:  Monika Długosz-Danecka; Sebastian Szmit; Tomasz Ogórka; Aleksander B Skotnicki; Wojciech Jurczak
Journal:  Cancer Med       Date:  2019-02-10       Impact factor: 4.452

4.  Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan.

Authors:  T J McElwain; D W Hedley; G Burton; H M Clink; M Y Gordon; M Jarman; C A Juttner; J L Millar; R A Milsted; G Prentice; I E Smith; D Spence; M Woods
Journal:  Br J Cancer       Date:  1979-07       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.